Genetic changes in the spectrum of neuroendocrine lung tumors

Cancer

Volumn 85, Issue 3, 1999, Pages 600-607

  Onuki, Naoyoshi ^a,b   Wistuba, Ignacio I ^a   Travis, William D ^c   Virmani, Arvind K ^a,d   Yashima, Kazuo ^a   Brambilla, Elizabeth ^e   Hasleton, Phillip ^f   Gazdar, Adi F ^a,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e HÔPITAL MICHALLON   (France)

^f WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Chromosome 3p; Chromosome 5q; MEN1 gene; Neuroendocrine tumors; p53 gene; Pulmonary carcinoids; ras gene; Small cell carcinoma of the lung

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME 3P; CHROMOSOME 5P; HUMAN; HUMAN TISSUE; LUNG TUMOR; NEUROENDOCRINE TUMOR; ONCOGENE RAS; POINT MUTATION; PRIORITY JOURNAL; TUMOR CLASSIFICATION;

CARCINOID TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 5; CHROMOSOMES, HUMAN, PAIR 9; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; POINT MUTATION; SURVIVAL ANALYSIS;

EID: 0033083898     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990201)85:3<600::AID-CNCR10>3.0.CO;2-W     Document Type: Article

References (28)

1. Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr., Nieman L, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991;15(6):529-53.
2. Vuitch F, Sekido Y, Fong K, Mackay B, Minna JD, Gazdar AF. Neuroendocrine tumors of the lung. Pathology and molecular biology. Chest Surg Clin N Am 1997;7:21-47.
3. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972;64:413-21.
4. Minna JD, Sekido Y, Fong K, Gazdar AF. Molecular biology of lung cancer. In: DeVita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: J.B. Lippincott, 1997:849-57.
5. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246(4929):491-4.
6. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46.
7. Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mool WJ, Wagenaar SS, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988;48(5738):5738-41.
8. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991;6(1353):1353-62.
9. Wagner SN, Muller R, Boehm J, Putz B, Wunsch PH, Hofler H. Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. Virchows Arch B Cell Pathol Incl Mol Pathol 1993;63:325-9.
10. Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 1996; 148(5):1531-41.
11. Lai SL, Brauch H, Knutsen T, Johnson BE, Nau MM, Mitsudomi T, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res 1995;15(2):225-32.
12. Hurr K, Kemp B, Silver SA, el-Naggar AK. Microsatellite alteration at chromosome 3p loci in neuroendocrine and non-neuroendocrine lung tumors. Histogenetic and clinical relevance. Am J Pathol 1996;149:613-20.
13. Debelenko L, Brambilla E, Agarwal SK, Swallwell JI, Kester MB, Lubensky IA, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet 1997;6:13:2285-90.
14. Emmert-Buck MR, Lubensky IA, Dong Q, Manickam P, Guru SC, Kester MB, et al. Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Res 1997;57:1855-8.
15. Sugio K, Kishimoto Y, Virmani A, Hung JY, Gazdar AF. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994;54:5811-5.
16. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, Chen H, et al. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res 1997;57:3154-8.
17. Don RH, Cox PT, Wainwright BJ, Baker K, Mattick JS. 'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 1991;19(14):4008.
18. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
19. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-8.
20. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Roo K, et al. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res 1997;57(1):1-6.
21. Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Fong KM, et al. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 1997;57(3):400-3.
22. D'Amico D, Carbone DP, Johnson BE, Meltzer SJ, Minna JD. Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Cancer Res 1992;52:1996-9.
23. Lohmann DR, Fesseler B, Putz B, Reich U, Bohm J, Prauer H, et al. Infrequent mutations of the p53 gene in pulmonary carcinoid tumors. Cancer Res 1993;53:5797-801.
24. Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CH, et al. p53 mutations in human lung tumors. Cancer Res 1992;52: 1695-8.
25. Takeshima Y, Seyama T, Bennett WP, Akiyama M, Tokuoka S, Inai K, et al. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 1993;342:1520-1.
26. Harpole DH, Feldman JM, Buchanan S, Young WG, Wolfe WG. Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg 1992;54:50-4.
27. Knudson AG. Hereditary cancers: clues to mechanisms of carcinogenesis. Br J Cancer 1989;59(661):661-6.
28. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.